SKYRIZI® versus STELARA® head-to-head study in Crohn’s Disease meets all primary and secondary endpoints.
AbbVie today presented positive results from the head-to-head Phase 3 SEQUENCE study that evaluated the efficacy and safety of risankizumab (SKYRIZI®, 600 mg intravenous [IV] at week 0, 4 and 8 and 360 mg subcutaneous [SC] starting at week 12…